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Vitamin C is an essential micronutrient, a free radical scavenger; while it has 
functions such as blocking oncogenic transformation induced by carcinogens. 
A different view of the potential action of vitamin C in cancer came from the dis-
covery of its importance for activation of ten-eleven translocation (TET) enzymes 
that are involved in demethylation of DNA and histones. Aberrant DNA and histone 
methylation are hallmarks of all cancers and may result from altered expression or 
point mutations in the genes encoding these regulatory enzymes. Recent studies 
have shown that vitamin C potentiates the effects of DNA methyltransferase inhibi-
tors. Epigenetic alterations, along with genetic mutations, are known to contribute 
to onset of cancer. Vitamin C is found to be a key mediator of the interface between 
genome and environment, regulating DNA demethylation as a cofactor for TET 
dioxygenases. It is shown that vitamin C drives active removal of DNA methylation 
by enhancing TET enzymes, which helps to erase DNA methylation and epigenetic 
memory encoded by it to improve reprogramming of differentiated cells to an 
embryonic-like state. Here, an overview of the role of vitamin C as an essential 
factor for epigenetic regulation and its potential in epigenetic therapy in cancer 
patients is provided.
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1. Vitamin C
1.1 Vitamin C, free radicals and antioxidant mechanism
Vitamin C (l-ascorbic acid) is a multifunctional water-soluble antioxidant 
substance in both plants and animals, having vital and ubiquitous roles in the life 
processes. It was first isolated and characterized by Szent-Gyorgyi back in 1928 [1]. 
In plants especially in green leaves, this metabolite is one of the most abundant, 
representing 10% of the total soluble carbohydrate pool [2]. In both plants and 
animals, it has important roles as a cofactor for a large number of key enzymes, 
influencing mitosis and cell growth by modulating the expression of specific genes 
involved in defense and hormonal signaling pathways. It is also required for iron 
utilization, connective tissue, cardiovascular functions, and immune cell develop-
ment [3]. The disease, scurvy, which is defined as a medical situation caused by 
lack of l-ascorbic acid has considerable historical significance in the discovery of 
this amazing substance. In nineteenth century sailors and others who did not have 
access to natural sources of vitamin C (fresh vegetables and fruits) suffered from 
bleeding under the skin, severe ulcers, depression, loss of teeth and joint weakness [1]. 
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In an effort to find a cure, scientists discovered that by consuming certain  
vegetables and fruits, this condition can be treated and prevented from reoccur-
ring [1]. Plants and most animals synthesize vitamin C on their own, but humans 
lack this ability due to a deficiency in an enzyme called “l-gulono-gamma-lactone 
oxidase” [1–3] that catalyzes the final step in vitamin C biosynthesis, represent-
ing that humans must obtain this vital compound from exogenous sources such as 
natural diet and supplements.
Electrons prefer to pair up with each other so that they can remain energeti-
cally stable. However, due to biotic and abiotic influences such as infection, 
wounding, UV radiation, air pollutants, smoking, and natural oxygen metabolism 
(aerobic respiration), this balance is disrupted. Consequently various molecules 
can end up with a single electron in their outermost orbital, making them highly 
unstable and reactive towards their surroundings [4]. The newly formed molecule 
is now desperately looking for another electron to balance and stabilize itself 
with. This is what is known as a “free radical,” that are urgently searching for elec-
trons and stealing them from other molecules. When a molecule loses an electron 
to a free radical molecule, it becomes a free radical itself and should now find an 
electron from another molecule to energetically stabilize itself [4, 5]. By this way, 
a single free radical can initiate a chain reaction that can result in severe damage 
to cell membranes, organelles, and structural and genetic coding (DNA and RNA) 
of body [4, 5]. These destructive mechanisms result in chronic free radical assault 
(oxidative stress). On the contrary, living organisms have a large arsenal of active 
substances such as antioxidants, to scavenge them and fight back [4, 5]. Vitamin 
C is a highly potent (reducing agent) antioxidant capable of neutralizing reactive 
oxygen species (ROS) and nitrogen derived free radical species [4, 5], achieving 
this by donating an electron to free radicals (Figure 1). As being a small, water 
soluble, reductone sugar acid with antioxidant properties, vitamin C acts as a pri-
mary substrate for detoxification of a number of ROS such as H2O2, and neutralize 
it to superoxide radicals (O2
·−), singlet oxygen (O·−) or hydroxyl radical (OH·−) by 
acting as a secondary antioxidant during reductive recycling of the oxidized form 
of α-tocopherol [2, 4] (Figure 1).
1.2 Vitamin C and cancer
The carcinogenic effect of oxidative stress is focused on the genotoxicity of 
ROS. They can cause cancer through multiple mechanisms, and are known to play 
significant roles in the promotional stage of carcinogenesis [2, 4, 5]. Vitamin C 
is associated with its protective roles against ROS dependent oxidative stress, by 
stimulating immune function, inhibiting nitrosamine formation, and blocking 
the metabolic activation of carcinogens. It can also protect against oxidative DNA 
damage, that is implicated in tumor initiation [5, 6]. Although oxidative stress causes 
oxidative damage, moderate amounts of ROS are found to serve as a secondary mes-
senger in the intracellular signaling cascades [5, 6]. Low oxidative stress is proved to 
be essential for cellular signal transduction that leads to the induction of detoxifica-
tion or antioxidant enzyme systems. Limited amounts of ROS are needed for trig-
gering the antioxidant signal transduction [5, 6]. Some phytochemicals are proved 
to induce phase II detoxification of antioxidant enzymes by triggering nuclear 
translocation of the transcription factors such as NF-E2–related factor 2 (Nrf2) 
binding to antioxidant response element [7]. Many of the inducers are capable of 
activating these transcription factors mimic prooxidants; interestingly, most of them 
are antioxidants by nature [8]. Besides the antioxidant activity, prooxidant potential 
of vitamin C is contributed to its chemopreventive properties [8, 9]. Individuals 
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with cancer are reported to have significantly lower plasma vitamin C levels than 
healthy individuals [9]. Cancer-induced ROS formation and oxidative stress is one 
explanation for such a deficiency [10]. In this case, the prooxidant activity of vitamin 
C needs to be clarified while it is fighting, as an antioxidant, against oxidative stress. 
As a consequence, it is worthwhile to examine if vitamin C can induce the expression 
of phase II detoxification via its prooxidant potential, indicating that high intakes 
of vitamin C concentrations in serum are inversely associated with the risk of some 
cancers [10, 11].
Vitamin C at high doses has a very different (pro-oxidative) effect from vitamin C 
at physiological doses, that at high doses and under certain conditions (in the presence 
of redox-active metal ions) vitamin C can give rise to ROS, protein glycation, and DNA 
damage [11–13]. Increased levels of ROS and redox-active iron led to alterations in can-
cer cell oxidative metabolism resulting in selective sensitivity and pro-oxidative toxicity 
of high-dose vitamin C [11, 12]. It is reported that exposure to high-dose vitamin C 
sensitized cancer cells to ionizing radiation combined with chemotherapy [10–13].
1.3 Vitamin C and anti-inflammatory activity
It is evident that ROS are involved in chronic inflammation and cancer [14]. The 
generation of oxidative stress is an important part of the inflammatory response 
that is associated with tumor promotion. It is indicated that stomach cancer is a 
consequence of chronic inflammation [15]. This inflammatory process caused 
by the overproduction of ROS could be a target of vitamin C [15]. Vitamin C was 
proved to reduce inflammation caused by ROS [15], a recent study showed low 
vitamin C concentrations in gastric juice in the earlier stage of carcinogenesis 
[16]. Vitamin C protects gastric carcinogenesis by scavenging of the mucosal free 
radicals [15, 16] and by inhibiting the formation of carcinogenic nitrosamines 
[15, 16]. It is reported that, treatment of endothelial cells with vitamin C resulted 
Figure 1. 
Free radicals and antioxidant mechanism [2].
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Figure 2. 
Possible chemopreventive mechanisms of vitamin C in carcinogenesis. ROIs, reactive oxygen intermediates; 
GPx, glutathione peroxidase; GST, glutathione S-transferase; QR, quinone oxidoreductase; SOD, superoxide 
dismutase; CAT, catalase [24].
in the accumulation of a large amount of this substance inside the cells, which 
consequently decreased both the intracellular free radical status and inducible 
nitric oxide synthase induction [17]. During the inflammation process, vitamin C 
is shown to inactivate nuclear factor-B in endothelial cells besides of its antioxi-
dant activity [18], indicating the anti-inflammatory activity of vitamin C with its 
intrinsic antioxidant activity [16–18].
1.4 Vitamin C and cell-to-cell communication
In multicellular organisms, cell-to-cell communication through gap junction 
channels is essential for maintaining homeostatic balance through modulation 
of cell proliferation and differentiation [19]. Inhibition of this communication is 
related to the carcinogenic process, especially to tumor promotion [20]. A well-
known tumor promoter, hydrogen peroxide, is also found to inhibit gap junction 
intercellular communication (GJIC) [21]. It is found that the inhibition of GJIC 
is strongly linked to the biological phenomenon that involve the inflammatory 
and carcinogenic processes, suggesting that the inhibition of GJIC is involved 
in nongenotoxic cancer induction and tumor promotion [22]. It is reported that 
disruption of GJIC by hydrogen peroxide is protected by vitamin C [21], however, 
synthetic antioxidants such as Trolox has no ability to prevent hydrogen peroxide–
mediated inhibition of GJIC [22], indicating the role of vitamin C on GJIC appears 
to be related to a different mechanism, such as the inhibition of signal transduction 
[22–24]. Therefore, it can be hypothesized that the chemopreventive effects of  
vitamin C in carcinogenesis may be associated with the protective effects of vitamin C  
against epigenetic mechanisms, such as inflammation and inhibition of GJIC, as 
well as to antioxidant activities [24] (Figure 2).
2. Epigenetics
Theory of epigenetics takes attention at processes involving in multistage 
carcinogenesis, which promotional phase of carcinogenesis is a consequence of 
epigenetic events involving inflammation and the inhibition of GJIC, mediating by 
ROS [25, 26].
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2.1 DNA demethylation and family of TET dioxygenases
It is known that cancers are caused by genetic alterations. These are genetic 
changes in oncogenes, such as mutations, deletions, amplifications, rearrange-
ments and translocations, and changes in tumor suppressor or microRNA (miRNA) 
genes, that are involved in multistep carcinogenesis, and accumulate with tumor 
progression [27]. Nowadays, it is understood that classical genetics cannot explain 
all the properties of cancer alone, thus epigenetic abnormalities are also involved in 
tumorigenesis in addition to genetic alterations [27]. Thus, the epigenome means 
interface of environment and the genome. Epigenetic modifications catalyzed by 
certain enzymes and cofactors are the key to understanding molecular connections 
between the epigenome and the environment. Epigenetics is explained as heritable 
changes in gene expression that are not caused by DNA sequence alterations [28], 
including epigenetic alterations such as DNA methylation and histone modifica-
tions, that differ between cancer and normal cells [28]. The epigenome reflects 
the interface of a dynamic environment and the genome. Known epigenetic events 
include covalent modifications on nucleotides and histones, chromatin remodeling, 
and non-coding RNAs, which collectively constitute the epigenome [29].
Cytosine hydroxymethylation (5hmC) means of demethylating DNA and 
activating genes, which is a DNA modification associated with transcriptional 
silencing [30]. Methylation at the C5 position of cytosine (5-methylcytosine, 
5mC) is the major modification of DNA and plays important roles in regulating 
transcription and cellular identity [30]. Methylation at the C5 position of cytosine 
(5-methylcytosine, 5mC) is the major and best-characterized epigenetic mark of 
mammalian DNA. However, 5hmC was generally regarded as oxidatively dam-
aged cytosine in genome and may be replaced by DNA-repair mechanism [30, 31]. 
Methylation of DNA can change the functional state of regulatory regions, but it 
does not change the base pairing of cytosine, presenting epigenetic mark and is 
functionally involved in many forms of stable epigenetic repression [30, 31]. In 
honeybees DNA methylation patterns on cell and organismal fate is exemplified, in 
which differential DNA methylation determines whether the bee will be a worker 
or a queen [31, 32]. DNA methylation has also fundamental choices, such as gene 
silencing that leads to genomic imprinting, suppression of transposable elements, 
and the establishment of stable cellular identities [30–32], demonstrating that 
cellular reprogramming by nuclear transfer, cell fusion, and induced pluripotency 
can radically alter differentiated cellular states [33]. Epigenetic regulation by DNA 
methylation provides exciting insights into why reprogramming of cell fates is 
possible, showing that cytosines in mammalian cells can be hydroxymethylated 
to 5hmC (5-hydroxymethylcytosine). DNA methylation patterns are frequently 
observed in disease, particularly in cancer, including methylation of CGI promoters 
for tumor suppressor genes [34], supporting the recurring mutations in tumors, 
and thus providing insight into many aspects of biology and medicine. Factors 
that regulate methylation have been linked to human disease and contribute to 
malignances still remains largely unknown. The breakthrough in understanding the 
presence of 5hmC in the genome came from studies on a gene family that is known 
as ten-eleven translocation (TET) [35].
A group of enzymes termed methylcytosine dioxygenase ten-eleven trans-
location (TET, including TET1, TET2 and TET3) are identified to catalyze the 
hydroxylation of 5mC to 5-hydroxymethylcytosine (5hmC) [35, 36]. TET1 is 
located on human chromosome 10q21.3, TET2 on chromosome 4q24, and TET3 
on chromosome 2p13.1. TETs further oxidize 5hmC to 5-formylcytosine (5fC) 
and 5-carboxylcytosine (5caC) [37]. TETs belong to the Fe2+ and 2OG-dependent 
dioxygenase superfamily. All TET proteins contain a catalytic domain which binds 
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to Fe2+ and 2-oxoglutarate (2OG) to mediate oxidation of 5mC to 5hmC in DNA 
[37]. Subsequent experiments confirmed that TETs are Fe2+ and 2OG-dependent 
dioxygenases, and it is demonstrated that the catalytic activity of TETs is dependent 
on Fe2+ and 2OG. 2OG is also a critical intermediate metabolite of the Krebs cycle, 
and like collagen P4H, the catalytic activity of TET dioxygenases is indeed depen-
dent on Fe2+ and 2OG [37]. All TET proteins contain a C-terminal catalytic domain 
that consists of a cysteine-rich region and a double-stranded β-helix fold character-
istic of the Fe(II)- and 2-oxoglutarate (2-OG)-dependent dioxygenase superfamily 
[38]. These enzymes require Fe(II) as a cofactor metal and 2-OG as a cosubstrate 
to catalyze their reactions [38]. Demethylation of 5-methylcytosine (5mC) to 
5-hydroxymethyl cytosine (5hmC) is shown to be mediated by TET proteins [38]. 
TET1 is identified as a Fe2+ and 2OG-dependent enzyme that converts 5mC to 
5hmC. Thus, 5hmC, 5fC and 5caC have been proposed as demethylation intermedi-
ates. So far, our knowledge of TETs-mediated DNA demethylation is the following: 
the Fe2+ and 2OG-dependent TETs consecutively oxide 5mC to 5hmC, then to 5fC 
and 5caC which can eventually be removed from the genome and substituted by 
unmodified C, thus completing the process of DNA demethylation. Although it 
involves multiple steps, the TET-mediated oxidation in combination with base 
excision repair constitutes the most important and consistent pathway responsible 
for the active demethylation of DNA. As being a DNA demethylation intermediate, 
5hmC also serves as an epigenetic mark with unique regulatory functions [38–40].
2.2 Epigenetic alterations in cancer
It is demonstrated that tumor cells undergo various epigenetic modifications, 
DNA hypermethylation, that could lead to an imbalance in regulation of apoptotic 
genes, that is attributed as one of the important factors in the progression and treat-
ment of cancer [38–40]. There are also small non-coding miRNAs are reported as 
epigenetic regulators, recently, regulating gene expression through posttranscrip-
tional silencing of target genes.
2.2.1 miRNAs
In some cases, the prognosis and the progression of cancer are associated with 
changes in the expression of miRNAs during tumorigenesis. miRNAs lead to cleave the 
mRNA or inhibit translation, depending on the sequence complementarity between 
the miRNA and its target [41]. DNA methylation is a well-defined epigenetic mark. 
In humans DNA methylation occurs at cytosine residues in cytosine-guanine (CpG) 
dinucleotides and is controlled by enzymes called DNA methyltransferases (DNMTs), 
including DNMT1, DNMT3A and DNMT3B [42]. DNA hypermethylation by CpG 
promoter inactivating transcriptional tumor suppressor genes is known as one of 
the alterations that contributes to tumorigenesis in cancer cells [42]. In addition, 
cancer cells also undergoes hypomethylation at tissue-specific repetitive sequences, 
while these regions are heavily hypermethylated in normal cells [43], contributing 
DNA hypomethylation to tumorigenesis by causing chromosomal instability or the 
reactivation of transposable elements [44, 45]. On the other hand, endogenous repeat 
element-driven activation of the oncogenic tyrosine kinase, CSF1R, is suggested that 
impaired epigenetic control and the subsequent transcriptional derepression of repeat 
elements may play roles in tumorigenesis. It is demonstrated that oncogenes can be 
activated by the derepression of endogenous repeats, in addition to genetic and epigen-
etic modifications, suggesting that activation of normally silenced genes by promoter 
DNA hypomethylation is involved in tumorigenesis (Figure 2) [45]. miRNAs are 
also thought to play a role in tumorigenesis by modulating tumor suppressor genes or 
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oncogenes, as epigenetic regulators of DNA methylation and histone modifications 
[46], contributing to tumorigenesis by controlling various biological processes, such as 
proliferation, differentiation, and apoptosis through regulation of or interactions with 
oncogenes or tumor suppressor genes, acting either as an oncogene or tumor suppres-
sor gene depending on their target genes [47]. Up-regulation of miRNAs targeting 
tumor suppressor genes by overexpression, amplification, or epigenetic derepression 
might function as oncogenes inhibiting the activity of an anti-oncogenic pathway. By 
contrast, the genetic mutation, deletion or epigenetic silencing of a tumor suppressor 
miRNA that normally represses expression of oncogenes might result in derepression 
of oncogenes, thereby gain of oncogenic function. miRNAs have roles in the develop-
ment of tumors, are also implicated in tumor progression by affecting migration, 
adhesion, and invasion of cancer cells [45–47].
2.2.2 Histone modifications
The roles of epigenetics in the development and progression of tumors is well 
established. A little is known about the epigenetic activation of cancer-associated 
genes, although it is focused on the epigenetic inactivation of tumor suppressor genes 
during tumorigenesis and DNA hypomethylation of some genes. Histone modifica-
tions are also important epigenetic marks that are involved in chromatin structure 
and gene expression, in addition to DNA methylation, including covalent modifica-
tions of histone tail residues acting in DNA packaging and regulating transcriptional 
machinery to coding sequences [48]. These histone modifications occur at histone 
residues, such as lysine, arginine and serine (methylated, acetylated and phosphory-
lated) [48, 49]. Gene expression may be regulated by interactions between multiple 
histone modifications [49], for example, in a growing body. In contrast, aberrant 
histone modifications, in addition to DNA methylation, are recognized as important 
epigenetic changes during tumorigenesis [50]. Tumor-suppressor genes are enriched 
with active histone marks in normal cells, while the transcriptional silencing of those 
genes in cancer cells is reported to be associated with a loss of active histone marks, 
and are shown to be common features of human cancer cells [50].
Recently, it is reported that overexpression of cancer-promoting genes in cancer 
is associated with the loss of repressive histone modifications, suggesting over-
expression of oncogenes or cancer-promoting genes in tumors may contribute to 
tumorigenesis during epigenetic derepression (Figure 3). Epigenetically regulated 
genes may be promising therapeutic targets and biomarkers during tumor initia-
tion. In fact, epigenetic mechanisms involved in the regulation of cancer-associated 
genes possible epigenetic therapies targeting epigenetically dysregulated genes are 
contributed to the improvement of patient outcomes [51, 52] (Figure 3).
Vitamin C on DNA demethylation is also reported [53]. It is found that vitamin C  
could directly enhance the catalytic activity of TET dioxygenases by uniquely 
interacting with the C-terminal catalytic domain of TETs, modulating the epigen-
etic control of genome activity [53]. Vitamin C acting as a cofactor in DNA demeth-
ylation catalyzed by TETs, deficiency of this vitamin, results in disruption of the 
methylation-demethylation dynamics of DNA and histone, which can contribute to 
phenotypic alterations or diseases [53].
3. Vitamin C as an epigenetic agent
Vitamin C is an water-soluble micronutrient that exists as ascorbate anion under 
physiological pH conditions. It is well established that ascorbate is an essential 
cofactor in various enzymatic reactions and, also and antioxidant and free radical 
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scavenger. It assists collagen P4H to complete the hydroxylation and thus prevents 
scurvy; overall, it is required to maintain a number of Fe2+ and 2OG-dependent 
dioxygenases in their fully active forms [53]. In recent years, it is identified that a 
number of novel Fe2+ and 2OG-dependent dioxygenases catalyze the hydroxylation 
of methylated nucleic acids (DNA and RNA) and methylated histones. Methylation 
of DNA and histone are the major epigenetic hallmarks in the mammalian genome 
[53, 54]. It has been shown that some of these dioxygenases require ascorbate as a 
cofactor to start DNA demethylation and histone demethylation processes [53, 54].  
Vitamin C is suggested to effect the genome activity via regulating epigenomic 
processes [53, 54]. It serves as a cofactor TET dioxygenases that catalyze the oxida-
tion of 5mC into 5hmC. Vitamin C also required for the JmjC domain-containing 
histone demethylases, acting as a cofactor for histone demethylation [53, 54]. Thus, 
by participating in the demethylation of both DNA and histones, vitamin C appears 
to be a mediator between the genome and environment. These findings demon-
strate an unknown function of vitamin C in regulating the epigenome, which needs 
a re-evaluation of the functions of vitamin C in human health and diseases.
Life styles, such as smoking has effects on vitamin C availability. Smoking has 
also been shown to reduce vitamin C levels in the plasma, strongly [55]. Deficiency 
of vitamin C results in digestive diseases such as ulcerative colitis, Crohn’s disease, 
chronic gastrointestinal and kidney diseases [55, 56]. Insufficient vitamin C intake 
during pregnancy, affect the embryonic development due to the changing in the 
catalytic activity of TETs, resulting in certain types of developmental defects, such 
as neural tube defect (NTD), and also increases the risk of gastroschisis which is a 
congenital defect of the abdominal wall [57].
Vitamin C has a long controversial history as a treatment for cancer. As a 
cofactor for TETs, it enhances the catalytic activity of TETs in cancer cells, and 
acts in the reprogramming of cancer cells by enhancing the activity of TETs. 
In cancerous cells, the TET-mediated DNA active demethylation appears to be 
downregulated [34–40], and a low level of 5hmC is identified as a novel epigen-
etic hallmark of cancer [34–40]. Mutations in TETs lead to the loss of 5hmC in 
cancer [34–40]. If vitamin C is deficient, enzymatic activity of TETs are adversely 
effected, resulting in 5hmC reduction. Studies have demonstrated higher 
Figure 3. 
Epigenetic regulation of cancer-associated genes. Modified from [45].
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incidence of scurvy in cancer patients [58, 59]. An association between ascorbate 
transporters and cancer is also indicated [58, 59]. These findings suggest that 
vitamin C plays a critical role in the demethylation of DNA and histone, serv-
ing as a cofactor for TET, thus, deficiency of this vital vitamin may disrupt the 
methylation-demethylation dynamics of DNA and histone, and may contribute to 
phenotypic alterations in different cells along the developmental stages and aging, 
cancer and other diseases [58, 59], (Figure 4).
3.1 Vitamin C and epigenetic regulation in cancer
Studies over the past decades has declared that normal epigenetic regulation is 
disrupted during tumorigenesis [60], indicating that DNA methylation is the most 
common event in carcinogenesis [60]. DNA methylation of CpGs in promoters can 
result in silencing of various genes, including tumor suppressors [61], as a conse-
quence, disrupted gene expression in cancerous cells also can cause alterations in 
the methylation of lysine or arginine amino acids on histone tails [62].
Since hypermethylation of promoters of tumor suppressor genes been identi-
fied as one of the important factors supporting cancer development, demeth-
ylation agents are become the main focus of molecular-targeted therapeutics. 
Vitamin C is shown to play a central role in the conversion of 5mC to 5hmC by 
enhancing the catalytic activity of TET dioxygenases [56, 57], indicating, vita-
min C is an important factor in reducing the risk of promoter hypermethylation 
and supporting the maintenance of the 5hmC state that plays a major role in the 
epigenetic regulation [56–58].
3.1.1 Vitamin C and DNA demethylation
Requirement for vitamin C as an additional cofactor for dioxygenases indicated 
a potential role for this reducing vitamin in TET-mediated DNA demethylation, 
Figure 4. 
Epigenetic therapy. Modified from [45].
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suggesting that vitamin C has the capacity to modify DNA methylation in human 
cells [56], for instance, it is known that epigenetic reprogramming occurs during the 
embryonic development, which involves DNA demethylation and re-methylation. 
Vitamin C is found to cause DNA demethylation of nearly 2000 genes in embryonic 
stem cells [56]. These results indicate that vitamin C can be involved in the DNA 
demethylation process, however, it is unclear whether vitamin C participates directly 
in DNA demethylation or it is mediated by the enhanced catalytic activity of TETs by 
vitamin C. DNA hypermethylation is found at promoters of tumor suppressors and 
developmental genes, typically, whereas CpG sites in other gene regions are hypo-
methylated in cancerous cells. 5hmC is lower in a most of cancers, due to a loss of TET 
activity [56–58], as a result of inactivating mutations, down-regulation of TET gene 
expression, or insufficient supply of TET co-factors. In embryonic stem cells, in which 
vitamin C addition is shown to promote DNA demethylation through increased TET 
activity [63], supports the idea of sufficient vitamin C is important for maintenance of 
normal 5hmC levels. High-dose vitamin C is also shown to compensate for the loss of 
TET proteins [64]. Histone modifications and the expression of the genes that regulate 
these modifications are frequently disrupted in cancer by mutations, translocations/
amplifications, or deletions [65]. The loss of TET activity caused by DNA hyper-
methylation in vitro demonstrated increased methylation at tumor suppressor gene 
promoters [64, 65], suggesting that vitamin C is a cofactor for TET dioxygenases in the 
conversion of 5mC to 5hmC, thus modulating DNA demethylation [65] (Figure 5).
3.1.2 Vitamin C and histone demethylation
The basic unit of eukaryotic chromatin is composed of a short length of DNA 
wrapped around an octamer that consists of 2 copies of each histone (H2A, H2B, H3 
and H4), called nucleosome. Histones are substrates for post-translational modifica-
tions (PTM). PTMs on histones include methylation, acetylation, phosphorylation, 
and others [66]. The dynamic PTMs in the histone regulate genome stability, gene 
transcription and chromatin structure. Methylation at lysine and arginine amino 
acids is epigenetic modification in histones. Histone methylation is a key component 
Figure 5. 
The role of TET proteins in DNA demethylation [65].
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in the epigenome along with DNA methylation. The most studied methylation occurs 
on histone H3 at lysine (K) 4 (H3K4), H3K9, H3K27, H3K36, H3K79, H4K20 and on 
histone H3 at arginine (R) 2 (H3R2), H3R8, H3R17, H3R26, H4R3. The methyl donor 
in histone methylation is S-adenosylmethionine (SAM), the same donor for DNA 
methylation. JmjC domain histone demethylase 1 (JHDM1) was purified, which 
specifically demethylates H3K36 in the presence of Fe2+ and 2OG [67]. After a long 
time, 20 proteins that belong to the JmjC domain have been discovered to have 
the catalytic capacity to demethylate histones [67]. It is now known that the JmjC 
domain-containing histone demethylases, like TETs, also belong to the Fe2+ and 2OG 
dioxygenase superfamily, that demethylate mono-, di-, and trimethylated histone 
lysine residues [68], indicating that vitamin C is required for optimal catalytic activity 
of JHDM1 [68]. It appears to be important in the late phase of reprogramming from 
terminally differentiated cells, which is also involved in cell differentiation, such as T 
cell maturation, indicating the role of vitamin C in demethylation of DNA and his-
tone in T cell maturation [69]. The role of vitamin C in histone demethylation is only 
examined in in vitro assays, deducing that vitamin C can be a cofactor for the JmjC 
domain-containing histone demethylase family, thus modulating histone demethyl-
ation in a similar way as it does on DNA demethylation [68–70].
3.1.3 Vitamin C and the loss of 5hmC in cancer
In contrast to the high level of 5hmC in embryos, cancer cells have very low or 
undetectable 5hmC. It is reported that the loss of 5hmC is a novel epigenetic hallmark 
of most, especially in certain types of human cancer [56–58]. The loss of 5hmC is 
resulted in disruption in DNA methylation-demethylation processes leading to malig-
nant transformation [56–58]. Mutations in TETs or a decreased expression of TETs are 
also attributed to the loss of 5hmC in cancerous cells [56–58], requiring further studies 
to determine whether there is a local vitamin C deficiency in cancer cells. Linus Pauling 
proposed the treatment of cancer patients with intravenous vitamin C, in 1970s [71], 
followed by other investigators, such as Mutlu Demiray in Turkey, nowadays [72]. 
Epigenetic modulation of vitamin C in the gene activity might shed a new light on 
this issue. As a cofactor for TETs, vitamin C is found to maximize the catalytic activity 
of the TETs in cancer cells. In the light of these findings, it can be suggested that the 
rebuilding the 5hmC content can offer a potential treatment for certain cancers.
3.1.4 Vitamin C in epigenetic treatment of cancer
Vitamin C is a safe and well-tolerated dietary supplement that is utilized 
in patient care and in treating cancer. Tumor cells are known to be resistant to 
programmed cell death. It is considered to induce E-cadherin expression in sensi-
tizing tumor cells towards apoptosis [73], as increased expression of E-cadherin 
is declared to sensitize cancerous cells to cell death [74]. Thus, reactivation of 
E-cadherin seems to be an important target for epigenetic therapy in cancer. 
Researchers observed an increase in the expression of E-cadherin by a combination 
of 5-AZA + vitamin C [75]. They reported an increase in E-cadherin expression by 
treatment with vitamin C and highlighted the role of vitamin C as an epigenetic 
player, opening a window for vitamin C-enhanced, TET-dependent conversion 
of 5mC to 5hmC [75]. Vitamin C consumption may also increase the activity of 
other epigenetic regulators such as histone demethylases, for which new drugs are 
currently being developed. Based on the effects of vitamin C on the methylation of 
DNA and histones, epigenetic regulation has implications in all cancers.
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4. Conclusion
Vitamin C is an essential compound with functions far beyond scurvy 
prevention. As an important mediator between genome and environment, it 
participates in the demethylation of DNA and histones, epigenome. Genetic and 
environmental factors that influence the synthesis, absorption, transportation 
and metabolism of vitamin C could have significant consequences for health and 
disease by regulating the epigenetic control of genome activity. Cancer is driven 
by epigenetic modifications along with genetic changes. Vitamin C activates the 
TET enzymes which are responsible for the removal of methyl groups for DNA 
and histones, regulating DNA demethylation as an essential cofactor for TET 
dioxygenases, and regulating histone demethylation as an essential cofactor for 
Jmjc domain-containing histone demethylases. Deficiency in vitamin C contrib-
utes to different diseases, resulting of failure to maintain the catalytic activity of 
TET dioxygenases and Jmjc domain-containing histone demethylases. Diet and 
lifestyle are known to affect the level of vitamin C in the human body, dramati-
cally. Deficiency in vitamin C is seen in cancer patients frequently, thus, adequate 
dietary vitamin C in these patients is needed increasingly, who have mutations 
in epigenetic regulators. This novel epigenetic function of vitamin C needs to 
become recognized by the general public. Future studies needs be done for greater 
understanding of vitamin C impact upon TET and the epigenome which have 
medicinal relevance in cancer and other diseases.
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